These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29216997)

  • 1. The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel.
    Bangalore S; Bezerra HG; Rizik DG; Armstrong EJ; Samuels B; Naidu SS; Grines CL; Foster MT; Choi JW; Bertolet BD; Shah AP; Torguson R; Avula SB; Wang JC; Zidar JP; Maksoud A; Kalyanasundaram A; Yakubov SJ; Chehab BM; Spaedy AJ; Potluri SP; Caputo RP; Kondur A; Merritt RF; Kaki A; Quesada R; Parikh MA; Toma C; Matar F; DeGregorio J; Nicholson W; Batchelor W; Gollapudi R; Korngold E; Sumar R; Chrysant GS; Li J; Gordon JB; Dave RM; Attizzani GF; Stys TP; Gigliotti OS; Murphy BE; Ellis SG; Waksman R
    JACC Cardiovasc Interv; 2017 Dec; 10(23):2349-2359. PubMed ID: 29216997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes following target lesion revascularization for bioresorbable scaffold failure.
    Tanaka A; Ruparelia N; Kawamoto H; Sticchi A; Figini F; Carlino M; Chieffo A; Montorfano M; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):832-6. PubMed ID: 26331577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds.
    Gogas BD; Garcia-Garcia HM; Onuma Y; Muramatsu T; Farooq V; Bourantas CV; Serruys PW
    JACC Cardiovasc Interv; 2013 Mar; 6(3):211-21. PubMed ID: 23517830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioresorbable Scaffold: The Emerging Reality and Future Directions.
    Sotomi Y; Onuma Y; Collet C; Tenekecioglu E; Virmani R; Kleiman NS; Serruys PW
    Circ Res; 2017 Apr; 120(8):1341-1352. PubMed ID: 28408454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioresorbable Stents: Is This Where We Are Headed?
    Wayangankar SA; Ellis SG
    Prog Cardiovasc Dis; 2015; 58(3):342-55. PubMed ID: 26319497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Current Literature on Bioabsorbable Stents: a Review.
    Omar WA; Kumbhani DJ
    Curr Atheroscler Rep; 2019 Nov; 21(12):54. PubMed ID: 31768641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
    Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of percutaneous coronary intervention with the Absorb bioresorbable scaffold: data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Grimfjärd P; James S; Persson J; Angerås O; Koul S; Omerovic E; Varenhorst C; Lagerqvist B; Erlinge D
    EuroIntervention; 2017 Dec; 13(11):1303-1310. PubMed ID: 28781242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioresorbable Coronary Scaffolds: Deployment Tips and Tricks and the Future of the Technology.
    Costa JR; Abizaid A
    Methodist Debakey Cardiovasc J; 2018; 14(1):42-49. PubMed ID: 29623171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions.
    Capodanno D; Angiolillo DJ
    JACC Cardiovasc Interv; 2017 Mar; 10(5):425-437. PubMed ID: 28279311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late stent thrombosis after the use of a bioresorbable vascular scaffold for the treatment of in-stent restenosis.
    Lee WC; Fang HY; Fang CY
    Coron Artery Dis; 2016 Dec; 27(8):709-710. PubMed ID: 27379437
    [No Abstract]   [Full Text] [Related]  

  • 19. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
    Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
    JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.